Z Squared Inc. current report, 27 April 2026

Business Context and Reporting Period

This Form 8-K is a current report filed by Coeptis Therapeutics Holdings, Inc. (the registrant) on April 28, 2026, regarding events occurring on April 27, 2026. The filing addresses a business combination between Z Squared, Inc. (NASDAQ: ZSQR) and Coeptis Therapeutics Holdings, Inc. It also covers a pro rata dividend distribution related to Coeptis's pre-business combination biopharmaceutical business.

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of corporate events rather than a financial performance report.

Material Changes

  • Business Combination: Z Squared, Inc. announced a business combination with Coeptis Therapeutics Holdings, Inc.
  • Dividend Distribution: A pro rata dividend distribution was issued related to Coeptis's pre-business combination biopharmaceutical business.

Guidance, Outlook, and Risks

The filing references a press release (Exhibit 99.1) for detailed information regarding the business combination and dividend distribution. No specific forward-looking guidance, management commentary on future performance, or detailed risk factors are included in the text of this Form 8-K summary.

Investor Verification Checklist

  • Verify the terms of the business combination between Z Squared, Inc. and Coeptis Therapeutics Holdings, Inc. in the attached press release.
  • Confirm the amount and timing of the pro rata dividend distribution related to the biopharmaceutical business.
  • Review the impact of the transaction on the capital structure of both entities.
  • Check for any subsequent filings detailing the financial implications of the merger.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.